In a filing, Celldex Therapeutics Inc revealed its PRESIDENT & CEO Marucci Anthony S acquired Company’s shares for reported $0.31 million on Nov 11 ’24. In the deal valued at $26.82 per share,11,500 shares were bought. As a result of this transaction, Marucci Anthony S now holds 40,284 shares worth roughly $0.9 million.
Then, Martin Samuel Bates sold 17,172 shares, generating $608,315 in total proceeds. Upon selling the shares at $35.42, the SVP AND CFO now owns 28,125 shares.
Before that, Crowley Elizabeth sold 30,000 shares. Celldex Therapeutics Inc shares valued at $1,045,962 were divested by the SR. VP & CPDO at a price of $34.87 per share. As a result of the transaction, Crowley Elizabeth now holds 9,074 shares, worth roughly $0.2 million.
UBS initiated its Celldex Therapeutics Inc [CLDX] rating to a Buy in a research note published on February 13, 2025; the price target was $44. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Goldman began covering CLDX with “Neutral” recommendation on September 30, 2024. Wolfe Research revised its rating on September 27, 2024. It rated CLDX as “a Peer perform” which previously was an “an Outperform”.
Price Performance Review of CLDX
On Friday, Celldex Therapeutics Inc [NASDAQ:CLDX] saw its stock fall -0.58% to $22.46. Over the last five days, the stock has lost -2.60%. Celldex Therapeutics Inc shares have fallen nearly -11.12% since the year began. Nevertheless, the stocks have fallen -41.66% over the past one year. While a 52-week high of $53.18 was reached on 01/08/25, a 52-week low of $20.91 was recorded on 02/12/25. SMA at 50 days reached $24.50, while 200 days put it at $31.95.
Levels Of Support And Resistance For CLDX Stock
The 24-hour chart illustrates a support level at 22.13, which if violated will result in even more drops to 21.80. On the upside, there is a resistance level at 23.08. A further resistance level may holdings at 23.70. The Relative Strength Index (RSI) on the 14-day chart is 42.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.33%. Stochastics %K at 39.47% indicates the stock is a holding.
The most recent change occurred on June 18, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $58 price target.
